Overview

Vaspect Study - An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia

Status:
Terminated
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
To document effectiveness, safety, and tolerability of donepezil in patients with mixed AD/VaD, and to further document the effectiveness, safety, and tolerability of donepezil in patients with VaD. The effects of donepezil on executive functioning, behavior, general cognition, ADLs and global functioning will be assessed.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Treatments:
Donepezil